Vraylar 2021 report




Published July 2022 • 26 Pages

The 5 Key Questions Addressed by this Report:

  • How many physicians were reached by Vraylar through reportable promotional activity in 2021 and how does this compare to its peer set in the Bipolar Disorder and Schizophrenia markets?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
  • How does AbbVie’s depth of coverage vary within key specialties (e.g., Nursing, Family Medicine, Internal Medicine, Physician Assistant, and Psychiatry) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Vraylar throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for Vraylar in 2021?

Data Sources and Methodology:

  • MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, over 5 years of longitudinal data is available – covering payments to more than 1,000,000 U.S. healthcare professionals.
  • Over 338,280 paid interactions across 57,330 physicians made on behalf of Vraylar were carefully examined to support our analysis. In addition, interaction data from 14 peer products (e.g. Abilify Maintena, Abilify Mycite, Aristada, Aristada Initio, Caplyta, Equetro, Fanapt, Invega Sustenna, Invega Trinza, Latuda, Lybalvi, Perseris, Rexulti, and Secuado ) was leveraged to provide benchmarking and market insights.